UNSPSC 51111627: Doxifluridine

This classification denotes a pyrimidine antagonist with the molecular formula C9H11FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1JK16Y2JP, chemically known as 1-((4s,2r,3r,5r)-3,4-dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione but generally known as doxifluridine, which bears US NIH Compound Identifier 18343. European Medicines Agency schedules Doxifluridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06389MIG.

UNSPSC 51111627 Doxifluridine is a Commodity code representing a specific pharmaceutical active ingredient; state and local procurement under this code appears minimal and indirect, tied to broader pharmacy benefit program sourcing rather than direct product acquisition. The single recent opportunity on record is the Texas Health and Human Services Commission's Request for Information (RFI) No. HHS0017013, posted April 3, 2026, which seeks vendor input on establishing direct-to-manufacturer prescription fulfillment arrangements as part of a Therapeutic Pharmacy Initiative. That RFI is fundamentally about pharmacy program structure and manufacturer contracting capability, not about procurement of doxifluridine itself — the code appears to have been assigned to the opportunity as a proxy for pharmaceutical sourcing broadly rather than as a genuine indicator of state and local demand for this specific compound.

The RFI does not specify budget, award value, or a formal response deadline, functioning instead as preliminary market intelligence to inform Texas HHS's future procurement strategy before a formal RFP is issued. State and local procurement activity under UNSPSC 51111627 as a discrete pharmaceutical ingredient line appears dormant in the recent record; procurement professionals should monitor whether Texas HHS issues a follow-on RFP that more precisely targets doxifluridine or other named pharmaceuticals, and whether other state Medicaid programs or health agencies begin issuing solicitations keyed to this code. The code's current visibility reflects program-level sourcing exploration rather than active competitive demand for the product itself.